



New York State Medicaid
NYRx Preferred Drug Program - 2026 Therapeutic Class Reviews
Preferred Drug Program Legislation

The New York State Medicaid Drug Utilization Review (DUR) Board intends to review the following therapeutic classes in 2026 as they pertain to the NYRx Preferred Drug Program (PDP). For the therapeutic classes listed below, new relevant clinical and/or financial information is known to exist.

Table with 3 columns: Therapeutic Category, Therapeutic Class, and Previous Review Date. Rows include Anti-Infectives, Cardiovascular, Dermatological Agents, Endocrine and Metabolic Agents, Hematological Agents, and Immunologic Agents.

Please refer to NYRx Preferred Drug List (PDL) for the list of drugs in the therapeutic class.

As of April 2026, no relevant new clinical and/or financial information is known to exist for the remaining PDP therapeutic classes, since previously reviewed, and the DOH proposes no changes to the NYRx PDL. If interested parties have new relevant clinical information, it can be submitted to dur@health.ny.gov as it becomes available.

In determining and submitting new clinical information, the previous review dates for all therapeutic classes are available on prior meeting agendas which may be viewed at the DUR



**Department
of Health**

**Office of
Health Insurance
Programs**

[Program](#) webpage. New clinical information may include a new drug or drug product information, new indications, new safety information or new published clinical trials. Comparative evidence is preferred, or placebo controlled when no head-to-head trials are available. Information in abstract form alone, posters, or unpublished data are poor quality evidence for the purpose of review and submission is discouraged.

DUR Board meeting agendas are posted to the [DUR Program](#) webpage thirty days prior to the meeting date. Please monitor the [DUR Program](#) webpage for DUR Board meeting schedules and agendas.